Boryung Pharmaceutical’s star Kanarb (fimasartan) has added a new indication after a decade. Now the drug is indicated to reduce proteinuria in a hypertensive diabetic patient. In the highly saturated market for angiotensin II receptor blocker (ARB) for hypertension, Kanarb has found a new weapon to break through the stagnated growth.

Besides the indication expansion, Boryung Pharmaceutical is also seeking for Kanarb combination drug, adding a variety of doses and expanding user age group to drive the prescription growth even after a ten-year anniversary.

◆A third ARB to be indicated to reduce proteinuria confirming superior effect than losartan

On Jan.